Thinking Differently About Rare Disease Therapies
Source: Life Science Leader
By Ben Comer, Chief Editor, Life Science Leader
In the 1990s, before large swaths of the biopharmaceutical industry turned toward rare disease drug development, Dr. Emil Kakkis, an assistant professor at Harbor-UCLA, began developing an enzyme to treat an exceedingly rare disease, known as mucopolysaccharidosis, or MPS I. It was the beginning of a journey that would ultimately lead to the founding of a rare and ultra-rare disease company — Ultragenyx — and the creation of a nonprofit patient advocacy organization — the EveryLife Foundation for Rare Diseases.
access the Magazine Article!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.
Subscribe to Life Science Leader
X
Subscribe to Life Science Leader
This website uses cookies to ensure you get the best experience on our website. Learn more